Literature DB >> 16966730

Health plans' strategies for managing outpatient specialty pharmaceuticals.

C Daniel Mullins1, Danielle Chauncey Lavallee, Françoise G Pradel, Andrea R DeVries, Nadine Caputo.   

Abstract

Balancing increased spending for specialty pharmaceuticals while providing affordable and equitable coverage for consumers is a key issue for public and private payers. Health plans rely on an array of strategies, including both medical management and those used for more traditional pharmaceuticals. To explore specific management strategies for outpatient specialty pharmaceuticals, a survey was administered to thirty-eight Blue Cross and Blue Shield plans, focused on identifying core strategies. Prior authorization was the most commonly used strategy, implemented by 83.3 percent of respondents. Other frequently implemented management strategies included claims review (82.8 percent), formulary management (76.7 percent), and utilization review (70 percent).

Entities:  

Mesh:

Year:  2006        PMID: 16966730     DOI: 10.1377/hlthaff.25.5.1332

Source DB:  PubMed          Journal:  Health Aff (Millwood)        ISSN: 0278-2715            Impact factor:   6.301


  5 in total

1.  Demonstrating the value of biologics: a call to action.

Authors:  Jeff Clough
Journal:  Biotechnol Healthc       Date:  2007-08

2.  Medicare formulary coverage for top-selling biologics.

Authors:  Su-Ying Liang; Jennifer S Haas; Kathryn A Phillips
Journal:  Nat Biotechnol       Date:  2009-12       Impact factor: 54.908

3.  Perks and Pitfalls of Performance-Linked Reimbursement for Novel Drugs: The Case of Sacubitril-Valsartan.

Authors:  Alexander T Sandhu; Paul A Heidenreich; John Lin; Justin Parizo; Jay Bhattacharya; Jeremy D Goldhaber-Fiebert
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2022-01-18

Review 4.  A review of approaches for the management of specialty pharmaceuticals in the United States.

Authors:  Bijal Nitin Patel; Patricia R Audet
Journal:  Pharmacoeconomics       Date:  2014-11       Impact factor: 4.981

5.  US Growth Hormone Use in the Idiopathic Short Stature Era: Trends in Insurer Payments and Patient Financial Burden.

Authors:  Adda Grimberg; Genevieve P Kanter
Journal:  J Endocr Soc       Date:  2019-08-28
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.